Dr. Suar’s group work on Salmonella Typhimurium (STm) and Salmonella Enteritidis (SEn) infection biology in Streptomycin pre-treated mouse model especially looking at identification of new virulence factors of SEn through comparative genome wide screening approach; development of recombinant and safe Salmonella derived mucosal vaccine candidates, which are even safe in immuno-compromised mouse models. Further translational work is under progress to develop enterocolitic vaccine against common gastro-intestinal pathogens such as Vibrio, Salmonella, E. coli and Shigella. Dr. Suar group also works on several projects like Characterization of efficient probiotics and study of their molecular basis of interaction with enteropathogenic microbes like Salmonella Enteritidis; Structural and Biological characterization of virulence proteins in SalmonellaTyphimuriumand investigating the functional role of differential alanine racemase gene of Salmonella Enteritidis; Exploring bacterial LPS modification: Its interaction with host and role in virulence; Transcriptomics of Salmonella with emphasis on the small non coding RNA complement involved in the acid tolerance response (ATR) and their influence on virulence and Identification and characterization of putative virulence factors inVibrio parahaemolyticus; Characterization of emerging MDR (Enterobacter) E. coli strains causing extended neonatal sepsis; Characterization of Type IV Pilin and pilin encoding islands in Salmonella enetrica serovar Enteritidis (P121509): Origins and interactions with phages; Novel cloning and chromosomal integration techniques, phage remodeling and vaccine development, construction of a modular genetic ALU; Synthesis of different nanoparticles and understanding their implication in biological systems.